Cara Therapeutic Stock Forecast:
According to predictions from 8 analysts, the average target price for Cara Therapeutic’s stock over the next year is USD 20.56. The analysts have rated the stock as a “Strong Buy”. However, Stock Target Advisor’s analysis of Cara Therapeutic’s stock signals a slightly bearish outlook based on 1 positive and 2 negative signals. As of the latest closing, the stock price was USD 10.02, which has decreased by -0.30% over the past week, -15.59% over the past month, and -6.36% over the last year.
Analysts Coverage Change:
- J.P. Morgan Chase & Co: Maintains “Overweight” rating and lowers the target price from to $16 from $19 on Cara Therapeutic‘s stock.
- H.C. Wainwright: Maintains “Buy” rating and lowers the target price to $20 from $25.
- Canaccord Genuity: Maintains “Buy” rating and lowers the target price from to $25 from $29.
- Piper Jaffray Companies: Maintains “Overweight” rating and lowers the target price from to $13 from $25.
- Needham & Company: Maintains “Buy” rating and lowers the target price from to $22 from $26.
Cara Therapeutics News:
Shares of Cara Therapeutics Inc. (CARA) took a dive on Tuesday morning, dropping nearly 30% after the commercial-stage biopharmaceutical company reported its fourth quarter results.
As of mid-morning trading, CARA was priced at $7.12, down $2.90 or 28.94%, on the Nasdaq. Over the past 52 weeks, the stock has traded between $6.98 and $13.97.
Despite a year-over-year increase in revenues for the quarter, rising from $821 thousand to $3.26 million, CARA reported a net loss of $30.3 million or $0.56 per share, compared to a loss of $33.4 million or $0.63 per share in the same quarter last year.
Investors were clearly disappointed by the reported loss, which was larger than anticipated, and it has led to a sharp drop in the company’s stock price. The market’s reaction to CARA’s fourth quarter results underscores the significant impact that earnings reports can have on a company’s valuation.
As always, it’s important for investors to carefully analyze a company’s financial statements and other relevant data before making any investment decisions. While CARA’s current stock price may be appealing to some, it’s essential to understand the risks involved and to conduct thorough due diligence before investing in any security.
FA Score (Fundamental Analysis):
The fundamental analysis of Cara Therapeutics is “Slightly Bearish” with a FA score of 3.3 out of 10, where 0 is very bearish and 10 is very bullish.
